Esophagus and esophageal-related cancers were not involved in this study.[6] A pharmacogenomic study showed that single nucleotide polymorphisms of AIM1L were associated with nausea and vomiting in cancer patients receiving opioid therapy.[7] Bioinformatics analysis suggested that AIM1L expression is higher in liver tumors compared to normal liver tissue, and hepatocellular carcinoma patients with high AIM1L expression generally have shorter OS. The gene discussed is CRYBG2; the disease is hepatocellular carcinoma.